News

Once again we will be attending the premier event for education, science, research and networking in nuclear medicine and molecular imaging - SNMMI 2023 - you will find us in Chicago, Illinois, June 24-27, Booth #3082. We have been an almost annual attendee of this...

Our General Manager Andreas Fintelmann is heading to Honolulu in May to attend the 25th iSRS conference. From 22-25.5. there will be an outstanding collection of plenaries and workshops. A great opportunity to reactivate old connections and make new ones while in the...

Meet ABX-CRO executives at the TRP 2022 Annual Meeting December 6-8 | Amsterdam. Join us for our presentation about taking Radipharmaceuticals to their next evulitionary level.

Meet ABX-CRO executives at the SNMMI 2022 Annual Meeting June 11-14 | Vancouver, BC, at booth no. # 649. Celebrate with us our inauguration of our Boston-based US branch ABX-CRO Inc., further strengthening our global operations, and see the latest version of QDOSETM,...

Andreas Fintelmann, leading radiopharmaceutical and precursor industry expert and executive joins ABX-CRO as managing director to support the further global expansion and growth of ABX-CRO. Andreas Fintelmann states “I am...

Preclinical and clinical evaluation of radiopharmaceuticals can be sometimes seen as straightforward compared to non-radioactive molecules as the injected doses are often below toxic doses. However, the development of theranostics requires highly specific expertise...

Speaking about why ABX-CRO decided to choose Flex Databases, Dr. Ulrike Schorr-Neufing said: The possibility of on-premise solutions for CTMS and eTMF as well as the flexibility of the different modules for managing clinical trials suits ABX-CRO very well. Flex...

ABX-CRO (Dresden, Germany), the globally leading full-service CRO for molecular imaging and radiotherapy, ONCODESIGN (ALONC -FR0011766229), a French biopharmaceutical company dedicated to precision medicine, Covalab (Bron, France), a biotechnology company specializing in the development and production of custom antibodies and CheMatech (Dijon, France), the European leader in the design announce their partnership. This strategic collaboration will launch the DRIVE™-MRT (Molecular RadioTherapy) solution. This innovative, premium service offer for therapeutic development is unique in nuclear medicine; it encompasses the full drug discovery process of theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimization, preclinical candidate drug generation and IND, to the design and management of clinical trials.